Beximco Pharmaceuticals Ltd informed the London Stock Exchange yesterday that it has requested the Bangladesh Securities and Exchange Commission (BSEC) for more time to submit and publish its financial statements for the period from July 2024 to March 2025.

 The company made the request as the BSEC's proposed appointment of nine additional independent non-executive directors to its board remains pending before the High Court of Bangladesh.

 In a disclosure to the London Stock Exchange, where it is listed, the drug maker said it has written to the BSEC, the Dhaka Stock Exchange, and the Chittagong Stock Exchange seeking the extension.

The request was made as the proposed appointment of nine additional independent non-executive directors to its board remains pending before High Court

 A meeting of the board of directors is required to approve the Q3 financial results, but it cannot be convened due to the pending decision regarding the independent directors.

 Further announcements will be made as appropriate, it said.